Published in Cancer Weekly, December 17th, 2002
The results will enable the company to proceed to the next stage of development of Pentrix, which is a potentially important treatment in the fight against cancer.
Pentrix is an "anti-idiotypic" (molecular mimic technology) vaccine that is intended to induce the body's immune system to attack tumors. All five patients who have completed the multidose trial to date have produced a strong immune response, giving the first indications of the potential...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.